Response to Jia and Wang

Xu Liu,Qi Liu,Xueting Yao,Miao Zhang,Cheng Cui,Haiyan Li,Dongyang Liu
DOI: https://doi.org/10.1093/cid/ciaa1390
2021-01-01
Abstract:hours postinfection, Vero cells), which was about 6-fold higher than that of Yao et al [7]. In brief, the determination of EC50 value in vitro can be significantly influenced by many experimental factors, and there is a marked difference between labs even if the method is the same. Because the parameter RLTEC (Ctrough,lung/EC50) is the key pharmacodynamics index in evaluation of dosing regimen for antiviral drugs based on PBPK modeling and in vitro antiviral activity, the factors affecting the EC50 analysis should be taken into account. In addition, the measurement of antiviral activity (EC50 value) in vitro requires rigorous methods, and the EC50 value alone is not sufficient to judge a drug’s in vivo antiviral activity [10].
What problem does this paper attempt to address?